Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist

Autonomic Neuroscience: Basic and Clinical

Volumn 166, Issue 1-2, 2012, Pages 35-38

  Santos Silva, André ^c   Charrua, Ana ^a,b   Cruz, Célia D ^a,b   Gharat, Laxmikant ^d   Avelino, António ^a,b   Cruz, Francisco ^a,b,c  

^a Inst of Pharmacol and Therapeutics   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d Glenmark Pharmaceuticals Limited   (India)

Author keywords

Bladder overactivity; GRC 6211; Spinalization; TRPV1; Urinary bladder

Indexed keywords

GRC 6211; KETAMINE; MEDETOMIDINE; UNCLASSIFIED DRUG; URETHAN; VANILLOID RECEPTOR 1 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CONTRACTION; BLADDER PRESSURE; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DOSE RESPONSE; FATIGUE; FEMALE; NEUROGENIC BLADDER; NEUROGENIC DETRUSOR OVERACTIVITY; NEUROGENIC DEXTRUSOR OVERACTIVITY; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; RAT; SPINAL CORD TRANSSECTION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PRESSURE; RATS; RATS, WISTAR; SPINAL CORD INJURIES; TREATMENT OUTCOME; TRPV CATION CHANNELS; UREA; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URODYNAMICS;

EID: 84855942949     PISSN: 15660702     EISSN: 18727484     Source Type: Journal    
DOI: 10.1016/j.autneu.2011.09.005     Document Type: Article

References (23)

1. Andersson K.E., Chapple C., Cardozo L., Cruz F., Hashim H., Michel M., Tannenbaum C., Wein A. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr. Opin. Urol. 2009, 19:380-394.
2. Avelino A., Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn-Schmiedeberg's Arch. Pharmacol. 2006, 373:287-299.
3. Birder L.A., Kanai A.J., de Groat W.C., Kiss S., Nealen M.L., Burke N.E., Dineley K.E., Watkins S., Reynolds I.J., Caterina M.J. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13396-13401.
4. Brady C.M., Apostolidis A.N., Harper M., Yiangou Y., Beckett A., Jacques T.S., Freeman A., Scaravilli F., Fowler C.J., Anand P. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. 2004, 93:770-776.
5. Charrua A., Cruz C.D., Cruz F., Avelino A. Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J. Urol. 2007, 177:1537-1541.
6. Charrua A., Cruz C.D., Narayanan S., Gharat L., Gullapalli S., Cruz F., Avelino A. GRC 6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J. Urol. 2009, 181:379-386.
7. Charrua A., Pinto R., Frias B., Cruz C.D., Cruz F. TRPV1 expression in the bladder is essential for NGF-induced detrusor overactivity. Abstract. Neurourol. Urodyn. 2009, 28:567-935.
8. Charrua A., Reguenga C., Cordeiro J.M., Correiade-Sá P., Paule C., Nagy I., Cruz F., Avelino A. Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. J. Urol. 2009, 182:2944-2950.
9. Chuang H.H., Prescott E.D., Kong H., Shields S., Jordt S.E., Basbaum A.I. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411:957-962.
10. Cruz F., Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol. Urodyn. 2007, 26:920-927.
11. Cruz F., Guimarães M., Silva C., Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997, 350:640-641.
12. Cruz C.D., Charrua A., Vieira E., Valente J., Avelino A., Cruz F. Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Exp. Neurol. 2008, 214:301-308.
13. de Groat W.C., Kawatani M., Hisamitsu T., Cheng C.L., Ma C.P., Thor K., Steers W., Roppolo J.R. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv. Syst. 1990, 30:S71-S77.
14. Dinis P., Silva J., Ribeiro M.J., Avelino A., Reis M., Cruz F. Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated stotage LUTS: a pilot study. Eur. Urol. 2004, 46:88-93.
15. Gavva N.R. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol. Sci. 2008, 29:550-557.
16. Huang W., Rubinstein J., Prieto A.R., Wang D.H. Enhanced postmyocardial infarction fibrosis via stimulation of the transforming growth factor-beta-Smad2 signaling pathway: role of transient receptor potential vanilloid type 1 channels. J. Hypertens. 2010, 28:367-376.
17. Ji R.R., Samad T.A., Jin S.X., Schmoll R., Woolf C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36:57-58.
18. Liu H.T., Chancellor M.B., Kuo H.C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol. 2009, 56:700-706.
19. Prescott E.D., Julius D. A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 2003, 300:1284-1288.
20. Seki S., Sasaki K., Fraser M.O., Igawa Y., Nishizawa O., Chancellor M.B., de Groat W.C., Yoshimura N. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J. Urol. 2002, 168:2269-2274.
21. Steiner A.A., Turek V.F., Almeida M.C., Burmeister J.J., Oliveira D.L., Roberts J.L., Bannon A.W., Norman M.H., Louis J.C., Treanor J.J., Gavva N.R., Romanovsky A.A. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J. Neurosci. 2007, 27:7459-7468.
22. Szallasi A., Cruz F., Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs?. Trends Mol. Med. 2006, 12:545-554.
23. Zhang X., Huang J., McNaughton P.A. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005, 24:4211-4223.